Inovio is a developer of vaccines, focusing around those that stimulate the immune system into fighting the disease or infection using the body's own capabilities.
US-based Inovio (NYSE: INO) is a developer of vaccines, focusing around those that stimulate the immune system into fighting the disease or infection using the body's own capabilities.
It believes that stimulating the body’s immune system remains one of the most promising approaches to addressing the unmet needs of cancers, HIV, hepatitis C virus, and other chronic infectious diseases. Its synthetic vaccine technology platform is progressively showing its potential to establish a new paradigm to prevent and treat these life-altering diseases. Inovio's growing pipeline of vaccine candidates based on this technology has now advanced to phase II clinical studies.
In oncology, it believes that immune tolerance - the inability of our immune system to distinguish cancerous cells from normal cells - is a major challenge and new approaches are needed to help the immune system to recognize diseased cells.
Its current pipeline includes therapies for cervical dysplasia, cervical cancer and head & neck cancer, all in phase I or II trials as of July 2014.